Select Publications

Blum W et al. Preliminary results of a phase II study of low dose decitabine as a single agent in older patients (age ≥ 60) with previously untreated acute myeloid leukemia (AML). Proc ASH 2008;Abstract 2957.

Blum W et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25(25):3884-91. Abstract

Borthakur G et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008;49(4):690-5. Abstract

Fenaux P et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): Results of the AZA-001 phase III study. Proc ASH 2007;Abstract 817.

Hellstrom-Lindberg E et al. Relationship of progression to acute myeloid leukemia (AML) from myelodysplastic syndrome (MDS) and cytogenetic status. Proc ASCO 2008;Abstract 7089.

Kantarjian HM et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: Comparison with historical experience. Cancer 2007a;109(6):1133-7. Abstract

Kantarjian HM et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007b;109(2):265-73. Abstract

List AF et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. Proc ASCO 2008;Abstract 7006.

Santini V et al. Patient outcome measures prolonged survival in patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA). Proc ASCO 2008;Abstract 7028.

Silverman LR et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20(10):2429-40. Abstract

Wijermans P et al. Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 2000;18(5):956-62. Abstract

 

 

 

 

Table of Contents

Top of Page

Home

EDITOR
Neil Love, MD

INTERVIEWS
Gail J Roboz, MD
- Select publications

Stephanie A Gregory, MD
- Select publications

Sundar Jagannath, MD
- Select publications

Guillermo Garcia-Manero, MD
- Select publications

Hematologic Oncology Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office